

Cynthia V Calkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9418655/publications.pdf>

Version: 2024-02-01

32
papers

1,240
citations

430754

18
h-index

501076

28
g-index

34
all docs

34
docs citations

34
times ranked

1803
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment"™™ by Pamuk and Hasni. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e124-e124.	0.5	2
2	Correction of depression-associated circadian rhythm abnormalities is associated with lithium response in bipolar disorder. <i>Bipolar Disorders</i> , 2022, 24, 521-529.	1.1	8
3	Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study). <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	1.1	28
4	Reversal of insulin resistance is associated with repair of blood-brain barrier dysfunction and remission in a patient with treatment-resistant bipolar depression. <i>Bipolar Disorders</i> , 2022, 24, 553-555.	1.1	0
5	Symptoms reported by Canadians posted in Havana are linked with reduced white matter fibre density. <i>Brain Communications</i> , 2022, 4, fcac053.	1.5	3
6	Role of autoantibodies and blood-brain barrier leakage in cognitive impairment in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2022, 9, e000668.	1.1	6
7	Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study. <i>Bipolar Disorders</i> , 2021, 23, 821-831.	1.1	20
8	Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2021, 12, 636174.	1.3	14
9	Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression. <i>NeuroImage: Clinical</i> , 2020, 26, 102049.	1.4	61
10	Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1580-1587.	0.5	39
11	The association between lithium use and neurocognitive performance in patients with bipolar disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 1743-1749.	2.8	28
12	Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. <i>Annals of Medicine</i> , 2019, 51, 281-293.	1.5	22
13	159. Brain Microvascular Pathology is Associated With Bipolar Neuroprogression. <i>Biological Psychiatry</i> , 2019, 85, S66.	0.7	1
14	Chronotype and cellular circadian rhythms predict the clinical response to lithium maintenance treatment in patients with bipolar disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 620-628.	2.8	80
15	Course of bipolar illness worsens after onset of insulin resistance. <i>Journal of Psychiatric Research</i> , 2018, 102, 34-37.	1.5	21
16	T127. Blood-Brain Barrier Dysfunction as a Biomarker for Neuroprogression in Bipolar Disorder. <i>Biological Psychiatry</i> , 2018, 83, S177.	0.7	0
17	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	1.3	18
18	Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 27.	0.8	81

#	ARTICLE	IF	CITATIONS
19	The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. <i>BMC Psychiatry</i> , 2016, 16, 129.	1.1	61
20	Insulin resistance in bipolar disorder: relevance to routine clinical care. <i>Bipolar Disorders</i> , 2015, 17, 683-688.	1.1	14
21	Early-onset and very-early-onset bipolar disorder: distinct or similar clinical conditions?. <i>Bipolar Disorders</i> , 2015, 17, 814-820.	1.1	26
22	Type 2 Diabetes Mellitus: A Potentially Modifiable Risk Factor for Neurochemical Brain Changes in Bipolar Disorders. <i>Biological Psychiatry</i> , 2015, 77, 295-303.	0.7	42
23	Insulin resistance and outcome in bipolar disorder. <i>British Journal of Psychiatry</i> , 2015, 206, 52-57.	1.7	120
24	Insulin Resistance, Diabetes Mellitus, and Brain Structure in Bipolar Disorders. <i>Neuropsychopharmacology</i> , 2014, 39, 2910-2918.	2.8	67
25	The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders. <i>Annals of Medicine</i> , 2013, 45, 171-181.	1.5	111
26	Repeated Erythromycin/Codeine-Induced Psychotic Mania. <i>Clinical Neuropharmacology</i> , 2013, 36, 177-178.	0.2	9
27	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. <i>PLoS ONE</i> , 2013, 8, e65636.	1.1	156
28	Beyond the Guidelines for Bipolar Disorder: Practical Issues in Long-Term Treatment with Lithium. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 437-445.	0.9	14
29	Can body mass index help predict outcome in patients with bipolar disorder?. <i>Bipolar Disorders</i> , 2009, 11, 650-656.	1.1	144
30	Treatment of bipolar disorder: New perspectives. <i>Annals of Medicine</i> , 2009, 41, 186-196.	1.5	25
31	Certain eating disorders may be a neuropsychiatric manifestation of PANDAS: case report. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2007, 16, 132-5.	0.7	10
32	Resting state functional connectivity in SLE patients and association with cognitive impairment and blood-brain barrier permeability. <i>Rheumatology</i> , 0, , .	0.9	1